Abstract
Knowing the mutational basis of a disease does not always explain the mechanism of pathogenesis, particularly when little is known about the disease-associated proteins themselves. This is very likely to be an ever-growing problem in the genomics era. The polyglutamine (polyQ) repeat disorders are an intriguing example of such a scientific dilemma. These human diseases presently include the spinocerebellar ataxia type 1 (SCA1, SCA2, SCA3, SCA6, SCA7), Huntington disease (HD), spinal and bulbar muscular atrophy (SBMA), and dentatorubropallidoluysian atrophy (DRPLA) (1). With the exception of SBMA and SCA6, due to the expansion of a polyQ in the androgen receptor and alpha1A voltage-dependent calcium channel, respectively, the wild-type function of the gene products are not understood. While the cloning of the polyQ genes has provided important genetic information, the biochemical mechanism responsible for each was not readily apparent. To gain insight into the molecular basis of polyQ-induced pathogenesis, investigators have turned to the development and characterization of disease models. Transgenic mice, in combination with cell culture models, have proven to be very useful tools for elucidating factors important for polyQ pathogenesis. This review focuses on those polyQ diseases for which informative studies have been undertaken using transgenic mice. For each disease, relevant information gleaned from other experimental approaches is also incorporated into the discussion.
Keywords: polyglutamine disease, transgenic mice, huntington, calcium channel, polyQ gene, SCA2, SBMA, protein misfolding, proteolysis
Current Genomics
Title: Expanding our Understanding of Polyglutamine Disease Through Transgenic Mice
Volume: 2 Issue: 1
Author(s): Jennifer D. Davidson and Harry T. Orr
Affiliation:
Keywords: polyglutamine disease, transgenic mice, huntington, calcium channel, polyQ gene, SCA2, SBMA, protein misfolding, proteolysis
Abstract: Knowing the mutational basis of a disease does not always explain the mechanism of pathogenesis, particularly when little is known about the disease-associated proteins themselves. This is very likely to be an ever-growing problem in the genomics era. The polyglutamine (polyQ) repeat disorders are an intriguing example of such a scientific dilemma. These human diseases presently include the spinocerebellar ataxia type 1 (SCA1, SCA2, SCA3, SCA6, SCA7), Huntington disease (HD), spinal and bulbar muscular atrophy (SBMA), and dentatorubropallidoluysian atrophy (DRPLA) (1). With the exception of SBMA and SCA6, due to the expansion of a polyQ in the androgen receptor and alpha1A voltage-dependent calcium channel, respectively, the wild-type function of the gene products are not understood. While the cloning of the polyQ genes has provided important genetic information, the biochemical mechanism responsible for each was not readily apparent. To gain insight into the molecular basis of polyQ-induced pathogenesis, investigators have turned to the development and characterization of disease models. Transgenic mice, in combination with cell culture models, have proven to be very useful tools for elucidating factors important for polyQ pathogenesis. This review focuses on those polyQ diseases for which informative studies have been undertaken using transgenic mice. For each disease, relevant information gleaned from other experimental approaches is also incorporated into the discussion.
Export Options
About this article
Cite this article as:
Davidson D. Jennifer and Orr T. Harry, Expanding our Understanding of Polyglutamine Disease Through Transgenic Mice, Current Genomics 2001; 2 (1) . https://dx.doi.org/10.2174/1389202013351183
DOI https://dx.doi.org/10.2174/1389202013351183 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Adverse Effects of Smoking on Health Outcomes in Bipolar Disorder: A Review and Synthesis of Biological Mechanisms
Current Molecular Medicine MDMA Toxicity and Pathological Consequences: A Review About Experimental Data and Autopsy Findings
Current Pharmaceutical Biotechnology HIV-1 gp120 and Drugs of Abuse: Interactions in the Central Nervous System
Current HIV Research The Infectious Etiology of Alzheimer’s Disease
Current Neuropharmacology Disease Modifying Approaches for Alzheimers Pathology
Current Pharmaceutical Design Synthetic Glucocorticoids: Antenatal Administration and Long-term Implications
Current Pharmaceutical Design Bridging Over the Troubled Heterogeneity of SPG-Related Pathologies: Mechanisms Unite What Genetics Divide
Current Molecular Medicine Transglutaminase-Catalyzed Reactions Responsible for the Pathogenesis ofCeliac Disease and Neurodegenerative Diseases: From Basic Biochemistry to Clinic
Current Medicinal Chemistry The Animal Models of Dementia and Alzheimer’s Disease for Pre-Clinical Testing and Clinical Translation
Current Alzheimer Research The Effect of Cannabis on Perception of Time: A Critical Review
Current Pharmaceutical Design Imaging and Clinical Features of Neurocutaneous Melanosis in the Pediatric Population
Current Medical Imaging Cranial Ultrasound - Optimizing Utility in the NICU
Current Pediatric Reviews Biomarkers and Future Targets for Development in Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry Effect of PSEN1 mutations on MAPT methylation in early-onset Alzheimer’s disease
Current Alzheimer Research Targeting Myc in Pediatric Malignancies of the Central and Peripheral Nervous System
Current Cancer Drug Targets Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract
Current Pharmaceutical Design Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinsons Disease
Current Neuropharmacology Challenges in Neuronal Apoptosis
Current Alzheimer Research Microglia NLRP3 Inflammasomes Activation Involving Diabetic Neuroinflammation in Diabetic Mice and BV2 Cells
Current Pharmaceutical Design Hereditary Rickets. How Genetic Alterations Explain the Biochemical and Clinical Phenotypes
Endocrine, Metabolic & Immune Disorders - Drug Targets